Loading
Life sciences · Journal article
International Journal for Multidisciplinary Research · September 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Thalassemia is a widespread hereditary blood disorder, characterized by defective or impaired production of the ???? or ????-globin chains that make up hemoglobin. This imbalance leads to ineffective erythropoiesis, anemia and additional associated symptoms. Current therapeutic strategies largely rely on hematopoietic stem cell (HSC) transplantation as a curative approach. However, recent research illustrates the use of stem cell therapy and CRISPR/Cas gene editing technology as alternative treatment options. Beyond HSCs, mesenchymal stem cells (MSCs) can potentially ameliorate clinical manifestations due to their ability to differentiate into diverse cell types, while induced pluripotent stem cells (iPSCs) are re-engineered somatic cells that can be genetically modified for thalassemia treatment. Advances in clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) include the reactivation of fetal hemoglobin through editing of the erythroid-specific enhancer of BCL11A, direct correction of HBB mutations, and genetic alterations in iPSCs. This review synthesizes a variety of research, examining the therapeutic potential of stem cell therapy and CRISPR/Cas technology in the treatment of thalassemia.